Bone Graft & Substitutes Market Size, Trends & Forecast 2033

Advancements in Synthetic and Biologic Bone Graft Materials to Drive Bone Graft and Substitutes Market to USD 6.60 Bn by 2033 at 6.9% CAGR – Coherent Market Insights

The Global Bone Graft and Substitutes Market, by Product Type (Bone Grafts (Allografts and Xenografts) and Bone Graft Substitutes (Ceramics, Composites, Polymers, Demineralized Bone Matrix, Bone Morphogenetic Proteins, and Others)), by Application (Spinal Fusion, Dental Bone Grafts, Craniomaxillofacial, Joint Reconstruction, Trauma & Extremities, and Oncology), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at USD 4.40 Bn in 2026, and is expected to exhibit a CAGR of 6.9%, during the forecast period (2026-2033).

Market Driver

Rising Volume of Spinal Fusion Procedures

The increasing number of spinal fusion procedures is a major driver of the global bone graft and substitutes market, as these materials promote bone formation and stabilize the vertebrae during fusion. For instance, in February 2026, the American Academy of Orthopaedic Surgeons reported that the American Spine Registry had reached 466,078 cumulative procedures, representing a 36% increase from its previous annual report. TLIF and PLIF procedures accounted for 32.5% of registered lumbar cases, while anterior cervical discectomy and fusion represented 62.2% of cervical procedures. In January 2026, Cerapedics also announced expanded FDA-approved indications for its PearlMatrix P-15 Peptide Enhanced Bone Graft across all major lumbar interbody fusion approaches. Such procedural growth and broader availability of advanced biologic grafts are increasing product adoption in spinal surgery. (Source: American Academy of Orthopaedic Surgeons)

Market Opportunity

Expansion of Approved Indications for Biologic Bone Grafts

Broader regulatory indications are enabling advanced biologic grafts to be used across more spinal procedures. For instance, in February 2026, the U.S.FDA approved an expanded indication for Medtronic’s Infuse Bone Graft in transforaminal lumbar interbody fusion at one or two adjacent levels from L2 to S1 for patients with symptomatic degenerative disc disease. (Source: U.S.FDA)

Growing Clinical Evidence for Orthobiologic Therapies

Greater collection of real-world clinical evidence can improve physician confidence in biologic and regenerative graft materials. The American Academy of Orthopaedic Surgeons announced an Orthobiologics Registry pilot program for 2026 to measure real-world outcomes associated with orthobiologic therapies. Stronger evidence regarding safety, fusion outcomes, and patient recovery is expected to support broader clinical adoption of advanced graft substitutes. (Source: American Academy of Orthopaedic Surgeons)

Market Trends

Shift Toward Ready-to-Use and Minimally Invasive Formats

Ready-to-use, moldable, strip, foam, putty, and prefilled delivery formats are becoming more prominent because they simplify graft preparation and placement, particularly in minimally invasive surgery. Recent synthetic and peptide-enhanced products emphasize controlled delivery, containment, handling consistency, and compatibility with titanium, PEEK, and hybrid interbody cages.

Expansion of Bone Graft Indications in Spine Surgery

Manufacturers are pursuing broader regulatory indications so established biologic grafts can support more spinal-fusion approaches and implant combinations. In February 2026, Medtronic gained FDA approval for Infuse Bone Graft in one- and two-level TLIF procedures, extending its approved use across major lumbar fusion techniques.

Increasing Preference for Peptide-Enhanced Biologics

Peptide-enhanced and growth-factor-based products are gaining attention as surgeons seek clinically validated alternatives to local autograft harvesting. Cerapedics expanded PearlMatrix indications in January 2026 across multiple open and minimally invasive lumbar approaches, reflecting increased emphasis on biologic activity, fusion performance, and reduced donor-site morbidity.

Integration of Antibacterial Properties into Bone Fillers

Bone graft substitutes are increasingly being combined with infection-risk management features for complex orthopedic defects. In June 2026, the FDA classified resorbable calcium-salt bone void fillers containing an approved aminoglycoside antibacterial as Class II devices for long-bone defects at increased infection risk, supporting development of multifunctional graft products.

Growing Adoption of Advanced Synthetic Bone Grafts

Next-generation synthetic grafts are increasingly engineered to imitate cancellous bone through nanocrystalline surfaces, interconnected porosity, and resorbable calcium-phosphate matrices. Xtant Medical launched nanOss Strata in December 2025, while Stryker received FDA clearance for multiple Vitoss bioactive bone-graft configurations in April 2026, highlighting continued material innovation.

Greater Emphasis on Clinical and Real-World Evidence

Regulators and professional bodies are placing greater emphasis on standardized evidence generation for orthobiologics. FDA’s 2025 dental bone-grafting guidance encouraged consistent animal-study designs and consideration of suitable non-animal methods, while AAOS introduced registry and educational initiatives to strengthen the evaluation of safety, effectiveness, and real-world outcomes.

To know the latest trends and insights related to Global Bone Graft and Substitutes Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/bone-graft-and-substitutes-market-1050

Key takeaways of the Global Bone Graft and Substitutes Market

The global bone graft and substitutes market is expected to exhibit a CAGR of 6.9% during the forecast period (2026–2033), owing to increasing initiatives by key players to develop prominent bone graft and its substitutes.
Based on application, spinal fusion is expected to account for the largest market share of 60.9% in 2026, owing to high procedure volumes and advancements in osteoinductive graft materials. The American Spine Registry’s February 2026 report covered 466,078 procedures, representing a 36% increase from the previous report; TLIF/PLIF accounted for 32.5% of lumbar cases, while anterior cervical discectomy and fusion represented 62.2% of cervical procedures. Moreover, the FDA expanded the indication for Infuse Bone Graft to one- or two-level TLIF procedures in February 2026. (Source: Osteoporosis Foundation)
By region, North America is expected to dominate the global market with a 44.6% share in 2026, supported by advanced orthopedic infrastructure, strong reimbursement coverage, extensive surgical registries, and rapid regulatory adoption of innovative graft products. In 2026, hospitals, ambulatory surgery centers, and private practices across all 50 U.S. states contributed more than 5.5 million procedures to the AAOS Registry Program. CMS also added 560 procedure codes to the Ambulatory Surgical Center Covered Procedures List for 2026, strengthening access to outpatient surgical care. (Source: CMS.gov)
Based on product type, bone grafts are expected to hold the largest market share of 63.1% in 2026, supported by their established use in spinal fusion, fracture reconstruction, revision surgery, and other orthopedic procedures. In July 2026, the International Osteoporosis Foundation reported that 60–80% of patients presenting for knee replacement have osteopenia or osteoporosis, highlighting the substantial burden of poor bone quality among orthopedic surgical candidates. This expanding patient pool supports demand for graft materials that facilitate bone healing, structural support, and implant fixation. (Source: International Osteoporosis Foundation)
Major players operating in the global bone graft and substitutes market include Ace Surgical Supply Co., Inc., NovaBone Product, LLC., Exactech, Inc., Medtronic Plc., LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation., BioHorizons Implant Systems, Inc., Globus Medical, Inc., RTI Surgical, Inc., Geistlich Pharma, Megagen, Novadip Biosciences, Mesoblast Ltd., Alphatec Spine, Inc., Institut Straumann AG, NuVasive, Inc., OsteoMed LLC, KYERON Medical Innovations, ORTHOFIX INTERNATIONAL N.V., Johnson & Johnson, Bone Therapeutics SA, K2M Group Holdings, Inc., and OsteoNovus

Key Development

In January 2026, Cerapedics received U.S. FDA approval to expand the indications and labeling of PearlMatrix P-15 Peptide Enhanced Bone Graft for adults with lumbar degenerative disc disease. The Class III drug-device product can now be used across major lumbar interbody fusion approaches, including ALIF, PLIF, OLIF, LLIF, and TLIF, with additional titanium alloy and PEEK-titanium cages, broadening surgeon access to an accelerated bone-fusion solution for appropriate eligible spinal patients.
In March 2026, Biomimetic Innovations Ltd, medical innovation company received MHRA approval to begin a first-in-human clinical study of OsStic, an injectable synthetic bone void filler, in tibial plateau fracture fixation. The study, conducted at Leeds Teaching Hospitals, will assess safety, fracture reduction, bone healing, pain, mobility, and quality of life. OsStic is designed to harden rapidly, support subchondral bone, conform to irregular defects, and promote bone ingrowth and remodelling gradually.
In August 2026, BONESUPPORT announced that CMS had finalized a Diagnosis-Related Group reassignment for CERAMENT G under the fiscal 2027 Medicare inpatient payment rule. Qualifying cases using the gentamicin-eluting bone void filler will receive reimbursement through the highest-paying DRGs within relevant clinical categories. The change, effective October 1, 2026, is expected to improve hospital reimbursement for treating complex orthopedic infections in patients, including periprosthetic joint, fracture-related, and diabetes-related bone infections. (Source: BONESUPPORT)
In February 2026, Medtronic, medical technology company received FDA approval for Infuse Bone Graft in one- and two-level transforaminal lumbar interbody fusion procedures. The supporting randomized clinical study included 493 patients, with Infuse achieving fusion rates exceeding 90% in single-level TLIF and showing earlier radiographic fusion than local autograft. (Source: Medtronic)